Iterum Therapeutics company info

What does Iterum Therapeutics do?
Iterum Therapeutics (NASDAQ:ITRM) focuses on developing and commercializing drugs to treat infections caused by multi-drug resistant pathogens. A significant project in their portfolio is Sulopenem, an antibiotic designed to combat the rising threat of such infections, particularly in the urinary tract and the intra-abdominal region. The company's objective is to address the critical need for new antibiotics that can effectively treat resistant bacterial infections, aiming to improve outcomes for patients facing limited treatment options. Originally based in Ireland, Iterum Therapeutics is dedicated to innovation in the antibiotic space, seeking to make a meaningful difference in public health on a global scale.
Iterum Therapeutics  company media
Company Snapshot

Is Iterum Therapeutics a public or private company?

key
Ownership
Public

How many people does Iterum Therapeutics employ?

people
Employees
14

What sector is Iterum Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Iterum Therapeutics ?

location pin
Head Office
Dublin, Ireland

What year was Iterum Therapeutics founded?

founded flag
Year Founded
2015
What does Iterum Therapeutics specialise in?
/Antibiotic Development /Sulopenem Drugs /Clinical Trials /Pharmaceutical Innovations /Infection Treatments /Drug Commercialization

What are the products and/or services of Iterum Therapeutics ?

Overview of Iterum Therapeutics offerings
Sulopenem, a novel penem anti-infective compound for the treatment of multi-drug resistant infections.
Oral and IV formulations of sulopenem to address different stages and severities of infection.
Research and development focused on expanding the applicability and efficacy of sulopenem against a broader spectrum of pathogens.
Partnerships to explore co-development opportunities for their antimicrobial agents.
Clinical trials aimed at demonstrating the safety and effectiveness of their products in treating various infections.
Continued exploration of antibiotic resistance mechanisms to innovate and enhance their product pipeline.

Who is in the executive team of Iterum Therapeutics ?

Iterum Therapeutics leadership team
  • Mr. Corey N. Fishman
    Mr. Corey N. Fishman
    President, CEO & Director
  • Ms. Judith M. Matthews
    Ms. Judith M. Matthews
    Chief Financial Officer
  • Dr. Michael W. Dunne M.D.
    Dr. Michael W. Dunne M.D.
    Strategic Advisor & Director
  • Dr. Sailaja  Puttagunta M.D.
    Dr. Sailaja Puttagunta M.D.
    Chief Medical Officer
  • Mr. Tom  Loughman Ph.D.
    Mr. Tom Loughman Ph.D.
    Senior Vice President of Technical Operations
  • Ms. Louise  Barrett
    Ms. Louise Barrett
    Senior Vice President of Legal Affairs & Secretary
  • Dr. Steven I. Aronin M.D.
    Dr. Steven I. Aronin M.D.
    Senior VP & Head of Clinical Development